Sprycel

dasatinib

Tablet (oral) · NDA 021986

Last listed protection ended

September 28, 2026

The FDA listed 2 patents and 4 exclusivities for Sprycel, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

November 9, 2024Ended
Orphan drug exclusivity
FDA code ODE-164
February 4, 2025Ended
Patent 8,680,103
Claims the drug product
May 9, 2025Ended
Pediatric exclusivity
FDA code PED
August 4, 2025Ended
Patent 8,680,103
Pediatric extension: six more months
December 21, 2025Ended
Orphan drug exclusivity
FDA code ODE-225
March 28, 2026Ended
Patent 7,491,725
Claims the drug substance and the drug product
June 21, 2026Ended
Pediatric exclusivity
FDA code PED
September 28, 2026Ended
Patent 7,491,725
Pediatric extension: six more months